The complement system is a key component of innate and adaptive immune responses. Complement regulation is critical for prevention and control of disease. We have determined the crystal structure of the complement regulatory enzyme human factor I (fI). FI is in a proteolytically inactive form, demonstrating that it circulates in a zymogen-like state despite being fully processed to the mature sequence. Mapping of functional data from mutants of fI onto the structure suggests that this inactive form is maintained by the noncatalytic heavy-chain allosterically modulating activity of the light chain. Once the ternary complex of fI, a cofactor and a substrate is formed, the allosteric inhibition is released, and fI is oriented for cleavage. In addition to explaining how circulating fI is limited to cleaving only C3b/C4b, our model explains the molecular basis of disease-associated polymorphisms in fI and its cofactors.
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allostery | innate immunity | atypical hemolytic-uremic syndrome | serine protease T he complement system is a major component of innate and adaptive immunity whose efficient regulation is critical for prevention and control of disease (1) . This regulation is effected by host cells expressing and recruiting a series of proteins that protect them from complement-mediated destruction. A key step in this self-protection is the proteolytic cleavage of complement C3b (and its homolog C4b) by the serine protease complement factor I (fI) (2) in the presence of additional regulatory proteins termed "cofactors" (3) . In the absence of regulation by fI the alternative pathway of complement leads to continuous generation of fluid-phase and cell-surface-deposited C3b by a self-amplification loop: The more C3 is converted to C3b, the more C3 convertases are formed, resulting in the depletion of C3 (4) . With healthy levels of functional fI and its cofactors, the irreversible breakdown of C3b to iC3b has three effects: (i) arrest of the assembly of the C3 convertases on hostcell surfaces, thus avoiding inappropriate complement amplification; (ii) prevention of runaway C3 consumption in the fluid phase; and (iii) generation of the C3b cleavage fragments that go on to bind specific complement receptors and are involved in opsonization and triggering of the adaptive immune response (5) . The importance of this regulatory mechanism is highlighted by the fact that fI-deficient individuals suffer from recurring infections and that polymorphisms in or near the genes for fI (and its cofactors) can predispose the carriers to diseases such as systemic lupus erythematosus, atypical hemolytic-uremic syndrome (aHUS), membranoproliferative glomerulonephritis, and age-related macular degeneration (for a recent review, see ref. 6) .
During the last few years, biochemical and structural data for complement regulators and C3/C3b in complex with regulators and inhibitors (7) (8) (9) (10) (11) have significantly advanced our understanding of the molecular mechanisms underlying complement regulation (12) . To date, however, only low-resolution information about fI has been available (13, 14) . FI is synthesized as a single 66-kDa chain and is processed posttranslationally by the addition of six Asn-linked glycans (totaling 22 kDa) and the excision of a linker sequence (residues 318 RRKR 321 ), splitting the molecule into two chains linked by a single disulfide bond (15) (16) (17) . The noncatalytic heavy chain comprises an N-terminal region; an fI membrane attack complex (FIMAC) domain; a scavenger receptor cysteine-rich (SRCR) domain; two class A low-density lipoprotein receptor domains (LDLRA1 and LDLRA2); and a C-terminal region of unknown function that is a site of sequence variability across species (SI Appendix, Fig. S1 ). The catalytic light chain consists of a chymotrypsin-like serine protease (SP) domain.
In the absence of atomic-level structural information, several questions still surround fI-mediated complement regulation. Firstly, fI is unusual among serum proteases in that it neither circulates as an uncleaved proenzyme (16) nor has an endogenous inhibitor. Multiple mechanisms of control of activity have been suggested, such as direct inhibition of the active site (18), conformational changes in both protease and substrate (19) , and models based on the transient nature of the substrate/cofactor complex. Second, it is not known how fI acquires its exquisite specificity for the selected sites of cleavage in C3b and C4b (20) . Third, a number of fI point mutants have been engineered that show, against synthetic or natural substrates, increased rates of activity with respect to the wild-type enzyme (21, 22) , but no explanation for these observations has been proposed. Finally, because homology modeling of the whole fI is rendered unfeasible by its multidomain architecture, the understanding of fI gene polymorphisms associated with disease also is fraught with uncertainty.
Here we describe the crystal structure of intact human fI. Combining this and earlier structures with biochemical assays and with mapping of disease-associated mutations, we propose a model whereby the heavy chain of fI allosterically inhibits the serine protease domain until the C3b/cofactor complex is engaged.
Results and Discussion
Crystal Structure of Human FI. FI contains 20 disulfide bonds and has been expressed in insect and mammalian cells (22) , but yields are insufficient for crystallography. We therefore purified fI from pooled human serum, obtained crystals and diffraction data, and determined the structure at 2.7-Å resolution (SI Appendix, Table  S1 ). The final model (Fig. 1 ) comprises 1,864 (83%) of the 2,244 residues present in four copies of the protein in the asymmetric unit, which overlay well with an rmsd of 0.8 Å over 440 residues ( Fig. 2A) . Two Ca 2+ ions per molecule also are present, each bound to one of the LDLRA domains, and appear to play structural roles, being buried within the molecule (Fig. 2B) . The first GlcNAc residue of each of the six N-linked glycosylation sites [Asn residues 52, 85, 159, 446, 476, and 518 (17) ] is ordered and visible in the electron density (SI Appendix, Fig. S2 ). In addition to its four domains, the heavy chain contains two helices that were not predicted from sequence, one in its N-terminal region (residues 13-18) and one toward its C terminus (residues 292-303). Key structural features of the model are summarized in SI Appendix, Figs. S3-S5.
In agreement with the early electron microscopy and solutionscattering data (13, 14) , the shape of fI is bilobal, with the heavy and light chains making up the two halves of a "brick" with the approximate dimensions 90 × 45 × 35 Å. The arrangement of the domains in the larger (heavy-chain) lobe forms a ring structure, with the N-terminal FIMAC domain contacting the C-terminal LDLRA domains. This contact is linked covalently by a disulfide bridge between Cys15 and Cys237 (Fig. 2C) . The heavy-chain N terminus and LDLRA2 domain also form one of the two interfaces between the heavy and light chains, the second being located around the interchain disulfide bridge Cys309-Cys435 (23) . Each chain buries about 720 Å 2 of surface in this interface (24) . Individually the domains of the heavy chain are mostly canonical (SI Appendix, Figs. S4 and S5). The smaller (lightchain) lobe is the SP domain, with the protease-active site presented on the end of the "brick" opposite the SRCR domain. This positioning, therefore, rules out a mechanism of self-inhibition by direct occlusion of the active site, despite the FIMAC domain's adopting a fold commonly found in serine protease inhibitors (18) .
Mature FI Is Zymogen-Like. As expected, the SP domain adopts a chymotrypsin-like fold organized around two six-stranded β-barrels with the active site at the barrel interface. Importantly, none of the four independent copies of fI in the crystal contains an SP domain in a proteolytically competent state. Many of the loops crucial to the formation of the serine protease active-site triad and oxyanion hole are disordered, and others are traceable only by reducing the electron-density contour level below 1.0 σ. These loops include residues 322-331, 377-389, 419-425, 454-466, 497-506, and 529-534. Thermal motion, as parameterized by atomic B factors, is also higher in these regions than in the core.
Most serum serine proteases are produced in a zymogen form with low activity and thus circulate without cleaving inappro- priate substrates. Activation is triggered by proteolysis of the bond between residues 321 and 322 (residues 15 and 16 in chymotrypsin numbering). The newly generated N terminus of residue 322 then forms a salt bridge with Asp506 (chymotrypsin Asp194) and facilitates the correct positioning of the neighboring catalytic Ser507 (Ser195). Structural studies of the transition from zymogen to active protease have demonstrated that the transition also entails a major reordering of several loops around the active site, the zymogen-activation domain (25) . Strikingly, four of the six flexible regions of fI correspond to this zymogenactivation domain (Fig. 3) . Our crystals therefore contain fI in a zymogen-like state, despite its having been processed at Ile322. Limited proteolysis of native fI under physiological conditions results in cleavage of the SP domain at residues flexible in our structure (26) , including the five N-terminal residues that would be buried in the protease in its fully active form, suggesting that the crystal structure is representative of the structure in solution.
However, it is very unusual to observe a zymogen-like structure for a processed serine protease in a crystal, and it has been proposed that packing into the crystal environment induces order in loops that are unstructured in solution studies (23) .
Although fI is extreme in the zymogen-like nature of the proteolytically processed form of the enzyme, it is related most closely in terms of activity and regulation to allosterically regulated serine proteases such as thrombin, which recently has been demonstrated to have a dynamic zymogen-activation domain in solution that reorders in the presence of allosteric activators or substrate (23, 27) . High concentrations of peptide substrates, in the absence of cofactor, can induce low levels of fI activity (28, 29) , and substrate analog inhibitors also can bind in the absence of either C3b or cofactor (28, 30) . However, the nonsubstratelike, broad-spectrum protease inhibitor diisopropyl fluorophosphate is able to react with the active site serine only if fI is preincubated with C3b (19) . This requirement strongly suggests that substrate-induced remodeling of the active site is key to fI To gain insight into previously unexplained disease-associated gene polymorphisms and mutations known to alter cofactorassisted C3b/C4b cleavage by fI (21, 22, 32, 33) , we mapped them to our crystal structure (Fig. 4 and SI Appendix, Table S2 ). Many of the mutations are buried in the heavy-chain interdomain interfaces and are expected to affect its structure (Fig. 4A) . More importantly, all the mutants that display a significantly increased rate of activity toward synthetic or natural substrates (21, 22) cluster at the interface between the two chains, centered around 216-223 529-536 Fig. 3 . Zymogenicity of the fI serine protease domain. Overlay of trypsin (Protein Data Bank ID 3MI4) (green and purple) with the fI serine protease domain (gray). The catalytic triad of trypsin is shown as red sticks, and the region of the active site is circled in red. The activation domain loops and N terminus, which are mobile and disordered in trypsinogen (25) , are shown in purple and are labeled. Surrounding the overlay, the Cα trace of each component of the trypsin activation domain (purple: activation domain; green: surrounding region) is overlaid with the coordinates of the equivalent regions from the four independent molecules of fI. The fI N terminus is disordered in all but one copy of the molecule, and even here it is mobile (average B factor, 85 Å 2 ) and is not in an active conformation. Factor I activation loops 1 and 2 are not visible in the electron density in any of the four copies, and activation loop 3 can be built only in two copies (average B factor, 66 Å the N terminus of the heavy chain (Fig. 4B) . Alteration of the interchain region by these mutations therefore seems to relieve an inhibitory effect of the heavy chain on the activity of the SP domain. The inhibition suggests an allosteric mechanism whereby contacts between the heavy chain and residues 437-444 and 549-553 of the SP domain maintain the zymogen-activation domain in its zymogenic state. Such a mechanism is consistent with the observation that intact fI will not cleave C3b in the absence of cofactor, whereas purified SP domain does, albeit with altered specificity and low activity (25) . The mechanism is also analogous to the regulation of serine proteases such as factor VIIa (34, 35) and thrombin (23) , which have allosteric regulator binding sites at locations distant from the zymogenactivation domain or active site (SI Appendix, Fig. S6 ). Release of the inhibition then would involve alteration of the heavy-chain/ light-chain interface on binding to the cofactor:C3b complex.
Interactions between fI and cofactor/C3b clearly are crucial to the activity of fI (26, 28) . It is interesting that several mutations of fI that affect function are surface exposed [Lys51Ala, Arg62Ala, and the aHUS-associated Ala222Gly (21, 36, 37) ]. We therefore predict that these residues may map to the cofactor or C3b binding sites. Further understanding of these fI mutations clearly requires more detailed information on the fI-C3b and fIcofactor interactions.
Modeling the Ternary Complex of FI, Factor H, and C3b. To understand complement regulation by fI better, we modeled the C3b:factor H 1-4 (fH [1] [2] [3] [4] ):fI ternary complex by docking our fI crystal structure onto the structure of the C3b:fH 1-4 complex. In the presence of one of its cofactors, fI first cleaves C3b between Arg1281-Ser1282 (38), and our modeling focuses on the ternary complex leading to this cleavage, because subsequent proteolysis events are assumed to involve unfolding of the C1r/C1s/Uegf/ Bmp1 (CUB) domain of C3b. Existing structures of serine protease/substrate and serine protease/inhibitor complexes were used to define the relative orientation between the C3b peptide targeted for proteolysis and the barrels of the fI serine protease domain (SI Appendix, Fig. S7) .
The model shows fI docked in a groove between fH 1-3 and C3b (Fig. 5A) and provides a compelling model for the ternary complex as judged by a variety of criteria. First, the SRCR domain is not involved in any major contacts, in agreement with the observation that a monoclonal antibody specific to this domain does not interfere with fI cleavage of C3b (26, 39) . However, the rest of the heavy chain is involved intimately in packing against both cofactor and C3b. Second, fI bears six bulky Asn-linked glycans that constitute 25% of the mass of the glycoprotein, and the model places these glycans away from the major interaction surface (SI Appendix, Fig. S8 ). Third, there is an overall elec- trostatic complementarity, with the long edges of the fI brick bearing positive charges that pack against negatively charged regions of fH and C3b (SI Appendix, Fig. S9 ), consistent with the observed salt-dependency of the fI-fH and fI-C3b interactions (14, 40) . Most importantly, fI makes significant contacts with both C3b and the cofactor, in agreement with the need for the preformed, binary complex for activity. These interactions include the surface-exposed fI loss-of-function mutants Lys51, Arg62, and Ala222 (21, 36, 37) , whose mechanism previously was unexplained (Fig. 5B) . The fI footprint on the cofactor also involves residues previously implicated in cofactor activity by either mutational data or disease association in patients but unexplained by the fH 1-4 /C3b structure (Fig. 5C ). These residues include the aHUS-associated Arg35His mutation in fH 1 (7) that recently has been demonstrated to have decreased cofactor activity (41) . Two other residues associated with altered cofactor activity (fH Gln101 and Ile106) (42) lie at the site of the major interaction region of the cofactor with one of the mobile loops of the SP domain (fI 419-425) (Fig. 5C) . Also buried at this contact point are two residues, Ile122 and Glu124, conserved among the cofactors in fH but absent in the noncofactor, complement regulator, CD55.
Combining our crystal structures with the existing cofactor/ substrate complex and mutagenesis data allows us to propose a general model for fI regulation of complement ( Fig. 6 and Movie S1): (i) binding of the cofactor to C3b produces a stable platform onto which the fI can dock (43); (ii) binding of fI releases the allosteric inhibitory effects of the heavy chain and induces remodeling of the zymogen-activation domain; and (iii) the active site forms around the substrate loop for the primary cleavage event. This work thus answers some of the outstanding questions on the mode of fI activity, provides the structural basis for the understanding of the disease-associated fI mutations, and forms the basis for future work on the regulation of immunity by fI proteolysis of C3b/C4b.
Materials and Methods
Human FI Protein Purification. Human fI was purified from citrated, outdated human serum from the blood bank (HD Supplies) with three minor modifications of the protocol described in ref. 44 : (i) the serum was clarified by centrifugation; (ii) no protease inhibitors were used; and (iii) size-exclusion chromatography fractions containing fI in Tris-buffered saline (pH 7.2) were pooled and cleaned of IgGs and albumin with a Hi-Trap protein-G column (GE Healthcare) and an anti-human serum albumin column, respectively.
Human FI Crystallization, Data Collection, Data Processing, and Structure Determination. Crystals of human fI were grown by vapor diffusion in 400-nL sitting drops, using an OryxNano robot (Douglas Instruments), by mixing (3:2) the fI (14 mg/mL) with 20-23.5% (wt/vol) PEG 1,500, 0.1 M Na succinate (pH 4.0), and 1 mM CaCl 2 . Crystals were harvested, cryoprotected in mother liquor supplemented with 15% ethylene glycol, and flash frozen in liquid nitrogen. Diffraction data were collected at 100 K with X-rays of wavelength λ = 0.9795 Å on beamline I02 at the Diamond Light Source (Harwell). The data are tetartohedrally twinned. All data collection statistics are given in SI Appendix, Table S1 .
All datasets were indexed and scaled using XDS (45) . CCP4 programs were used throughout for structure determination (46) . All model building was done in Coot (47) . The structure of fI was determined by molecular replacement using Phaser with models for the individual domains (Protein Data Bank IDs:, in order of placement: SP:1EKB; SRCR:1BY2; LDLRAs:1J8E; FIMAC:3B4V) followed by iterative model building and refinement against intensities modeling the tetartohedral twinning in Refmac5. Fourfold non crystallographic symmetry (NCS) was used during iterative model building. Refinement statistics are reported in SI Appendix, Table S1 . The refined model and measured structure factor amplitudes have been deposited in the Protein Data Bank (ID 2XRC).
Although fI proteolysis of C3b with fH as a cofactor is most efficient at pH 5 or lower (48), we used a a C3(NH 3 ) proteolysis assay using fI from washed and redissolved crystals to determine whether the pH 4.5-5.0 range at which the crystals diffracting to high resolution grew had altered activity. SI Appendix, 
